Solventum shares rise as Q1 results show momentum in wound care, dental and coding solutions

Solventum (SOLV) reported first-quarter results that reflected ongoing transformation efforts, new product launches and portfolio changes, with management citing commercial execution and favorable volume and mix as drivers. CEO Bryan Hanson said performance came as the company managed separation work from 3M, ERP implementations, acquisitions and divestitures. He pointed to momentum in advanced wound care, dental and health information systems, including autonomous coding solutions and integration of Acera in the wound care business. Solventum traded at $71.99 after the earnings update, up 4.3% from $69.04 before the report. Investors are watching customer adoption of new products, the operational impact of a major U.S. ERP cutover, the company’s separation from 3M and progress on its “Transform for the Future” cost-savings program.